Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting?

References

• Toksvang LN, Lee SHR, Yang JJ, et al. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia. 2022;36(7):1749–1758. doi: 10.1038/s41375-022-01591-4
   PubMed Web of Science ®Google Scholar
• Knezevic CE, Clarke W. Cancer chemotherapy: the case for therapeutic drug monitoring. Ther Drug Monit. 2020;42(1):6–19. doi: 10.1097/FTD.0000000000000701
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Müller K, Mogensen SS, et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000 Res. 2017;6:444. doi: 10.12688/f1000research.10768.1
   PubMedGoogle Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi: 10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Widmer N, Bardin C, Chatelut E, et al. Review of therapeutic drug monitoring of anticancer drugs part two – targeted therapies. Eur J Cancer. 2014;50(12):2020–2036. doi: 10.1016/j.ejca.2014.04.015
   PubMed Web of Science ®Google Scholar
• Baccarani M, Dreyling M. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:iv105–iv107. doi: 10.1093/annonc/mdp143
   Google Scholar
• Jabbour E, Haddad FG, Short NJ, et al. Treatment of adults with philadelphia chromosome–positive acute lymphoblastic leukemia—from intensive chemotherapy combinations to chemotherapy-Free Regimens. JAMA Oncol. 2022;8(9):1340–1348. doi: 10.1001/jamaoncol.2022.2398
   PubMed Web of Science ®Google Scholar
• Kim HY, Martin JH, Mclachlan AJ, et al. Precision dosing of targeted anticancer drugs—challenges in the real world. Transl Cancer Res. 2017;6(S10):S1500–S1511. doi: 10.21037/tcr.2017.10.30
   Google Scholar
• Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Internal Medi. 2009;24(1):1–10. doi: 10.3904/kjim.2009.24.1.1
   PubMedGoogle Scholar
• Stojanova J, Carland JE, Murnion B, et al. Therapeutic drug monitoring in oncology - What’s out there: a bibliometric evaluation on the topic. Front Oncol. 2022;12:1–9. doi: 10.3389/fonc.2022.959741
   Web of Science ®Google Scholar
• Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123–3127. doi: 10.1002/cncr.26679
   PubMed Web of Science ®Google Scholar
• Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(S2):241–247. doi: 10.1007/s00277-015-2314-2
   Google Scholar
• Carofiglio F, Lopalco A, Lopedota A, et al. Bcr-abl tyrosine kinase inhibitors in the treatment of pediatric CML. Int J Mol Sci. 2020;21(12):4469. doi: 10.3390/ijms21124469
   PubMed Web of Science ®Google Scholar
• Tandon S, Deshpande R, Narula G, et al. Role of therapeutic drug monitoring and challenges in the management of infantile chronic myeloid leukemia. Pediatr Oncall. 2021;18(2):18. doi: 10.7199/ped.oncall.2021.16
   Google Scholar
• Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology. 2018;2018:137–145. doi: 10.1182/asheducation-2018.1.137
   PubMedGoogle Scholar
• Hunger SP, Mullighan CG, Longo DL. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–1552. doi: 10.1056/NEJMra1400972
   PubMed Web of Science ®Google Scholar
• Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524–2539. doi: 10.3324/haematol.2020.247031
   PubMed Web of Science ®Google Scholar
• Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s oncology group study AALL0031. Leukemia. 2014;28(7):1467–1471. doi: 10.1038/leu.2014.30
   PubMed Web of Science ®Google Scholar
• Tran TH, Hunger SP. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities. Semin Cancer Biol. 2022;84:144–152. doi: 10.1016/j.semcancer.2020.10.013
   PubMed Web of Science ®Google Scholar
• Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol. 2009;27(31):5175–5181. doi: 10.1200/JCO.2008.21.2514
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Roberts IAG, Iacobelli S, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;102(4):1224–1231. doi: 10.1182/blood-2002-12-3637
   PubMed Web of Science ®Google Scholar
• ML DB, Cario G, Moorman AV, et al. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematol. 2021;8(1):e55–e66. doi: 10.1016/S2352-3026(20)30353-7
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879–894.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18(4):930–937. doi: 10.1158/1078-0432.CCR-10-1613
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054–1061. doi: 10.1038/leu.2009.38
   PubMed Web of Science ®Google Scholar
• Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the french national phase IV trial. J Clin Oncol. 2011;29(20):2827–2832. doi: 10.1200/JCO.2010.32.7114
   PubMed Web of Science ®Google Scholar
• Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome–positive acute lymphoblastic leukemia: results of children’s oncology group trial AALL0622. J Clin Oncol. 2018;36(22):2306–2314. doi: 10.1200/JCO.2017.76.7228
   PubMed Web of Science ®Google Scholar
• Hijiya N, Zwaan CM, Rizzari C, et al. Pharmacokinetics of Nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or acute lymphoblastic leukemia. Clin Cancer Res. 2020;26(4):812–820. doi: 10.1158/1078-0432.CCR-19-0090
   PubMed Web of Science ®Google Scholar
• Shen S, Chen X, Cai J, et al. Effect of dasatinib vs imatinib in the treatment of pediatric philadelphia chromosome–positive acute lymphoblastic leukemia. JAMA Oncol. 2020;6(3):358. doi: 10.1001/jamaoncol.2019.5868
   PubMed Web of Science ®Google Scholar
• Jabbour E, Koller PB, Oehler VG, et al. Olverembatinib (HQP1351) overcomes ponatinib resistance in patients with heavily Pretreated/Refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [abstract no. 82]. Proceedings of the 64th Annual Meeting of American Society of Hematology; 2022 Dec 10-13; New Orleans, Louisiana.
   Google Scholar
• Cortes JE, Saikia T, Kim D-W, et al. Efficacy and safety of vodobatinib in patients (pts) with chronic phase Philadelphia Positive chronic Myeloid Leukemia (Ph+ CML): a Sub Group Analysis by Lines of Tyrosine Kinase Inhibitor (TKI) therapy [abstract no. 84]. Proceedings of the 64th Annual Meeting of American Society of Hematology; 2022 Dec 10-13; New Orleans, Louisiana.
   Google Scholar
• Gross SD, Eide CA, Burkard MR, et al. Elvn-001, a Next Generation ATP-Competitive ABL1 Tyrosine Kinase Inhibitor for the treatment of chronic myeloid leukemia [abstract no. 1336]. Proceedings of the 64th Annual Meeting of American Society of Hematology; 2022 Dec 10-13; New Orleans, Louisiana.
   Google Scholar
• Padula WV, RA L, SB D, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016;108(7):djw003. doi: 10.1093/jnci/djw003
   PubMedGoogle Scholar
• Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133(22):2374–2384.
   PubMed Web of Science ®Google Scholar
• Abou Dalle I, Kantarjian H, Burger J, et al. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019;8(15):6559–6565. doi: 10.1002/cam4.2545
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–1671. doi: 10.1038/leu.2016.104
   PubMed Web of Science ®Google Scholar
• Saydam G, Ali R, Demir AM, et al. The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Int J Hematol Oncol. 2022;11:IJH38.
   PubMedGoogle Scholar
• Shin H, Choi SY, Kee K-M, et al. Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia. Int J Hematol. 2020;111(3):417–426. doi: 10.1007/s12185-019-02805-9
   PubMed Web of Science ®Google Scholar
• Millot F, Guilhot J, Baruchel A, et al. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer. 2014;50(18):3206–3211. doi: 10.1016/j.ejca.2014.10.007
   PubMed Web of Science ®Google Scholar
• Samis J, Lee P, Zimmerman D, et al. Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer. 2016;63(8):1332–1338. doi: 10.1002/pbc.26028
   PubMed Web of Science ®Google Scholar
• Kondryn HJ, Edmondson CL, Hill J, et al. Treatment non-adherence in teenage and young adult patients with cancer. Lancet Oncol. 2011;12(1):100–108. doi: 10.1016/S1470-2045(10)70069-3
   PubMed Web of Science ®Google Scholar
• Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733–3736. doi: 10.1182/blood-2010-10-309807
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388. doi: 10.1200/JCO.2009.26.3087
   PubMed Web of Science ®Google Scholar
• Clarke WA, Chatelut E, Fotoohi AK, et al. Therapeutic drug monitoring in oncology: International Association of therapeutic drug monitoring and clinical toxicology consensus guidelines for imatinib therapy. Eur J Cancer. 2021;157:428–440. doi: 10.1016/j.ejca.2021.08.033
   PubMed Web of Science ®Google Scholar
• Millot F, Suttorp M, Ragot S, et al. Discontinuation of imatinib in children with chronic myeloid leukemia: a study from the international registry of childhood CML. Cancers. 2021;13(16):4102. doi: 10.3390/cancers13164102
   PubMed Web of Science ®Google Scholar
• Ford M, Mauro M, Aftandilian C, et al. Management of chronic myeloid leukemia in children and young adults. Curr Hematol Malig Rep. 2022;17(5):121–126. doi: 10.1007/s11899-022-00673-5
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Aureli S, Bondanini F, et al. Chronic myeloid leukemia and pregnancy: when dreams meet reality. State of the art, management and outcome of 41 cases, nilotinib placental transfer. J Clin Med. 2022;11(7):1801. doi: 10.3390/jcm11071801
   PubMed Web of Science ®Google Scholar
• Suttorp M, Bornhäuser M, Metzler M, et al. Pharmacology and pharmacokinetics of imatinib in pediatric patients. Expert Rev Clin Pharmacol. 2018;11(3):219–231. doi: 10.1080/17512433.2018.1398644
   PubMed Web of Science ®Google Scholar
• Nikolova Z, Peng B, Hubert M, et al. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chem Pharmacol. 2004;53(5):433–438. doi: 10.1007/s00280-003-0756-z
   PubMed Web of Science ®Google Scholar
• Yoo C, Ryu M-H, Kang BW, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol. 2010;28(9):1554–1559. doi: 10.1200/JCO.2009.26.5785
   PubMed Web of Science ®Google Scholar
• Pavlovsky C, Egorin MJ, Shah DD, et al. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. Pharmacother J Human Pharmacol Drug Ther. 2009;29(9):1152–1156. doi: 10.1592/phco.29.9.1152
   Google Scholar
• Josephs DH, Fisher DS, Spicer J, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors. Ther Drug Monit. 2013;35(5):562–587. doi: 10.1097/FTD.0b013e318292b931
   PubMed Web of Science ®Google Scholar
• Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22(5):935–942. doi: 10.1200/JCO.2004.03.050
   PubMed Web of Science ®Google Scholar
• Miura M. Therapeutic drug monitoring of imatinib, Nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull. 2015;38(5):645–654. doi: 10.1248/bpb.b15-00103
   PubMed Web of Science ®Google Scholar
• Gandia P, Arellano C, Lafont T, et al. Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed? Cancer Chem Pharmacol. 2013;71(2):531–536. doi: 10.1007/s00280-012-2035-3
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction ofIn vivo activity in humans. J Pharmacokinet Biopharm. 1996;24(5):475–490. doi: 10.1007/BF02353475
   PubMedGoogle Scholar
• Bornhäuser M, Pursche S, Bonin M, et al. Elimination of imatinib mesylate and its metabolite N -Desmethyl-imatinib. J Clin Oncol. 2005;23(16):3855–3856. doi: 10.1200/JCO.2005.05.246
   PubMed Web of Science ®Google Scholar
• Le Coutre P, Kreuzer KA, Pursche S, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol. 2004;53(4):313–323. doi: 10.1007/s00280-003-0741-6
   PubMed Web of Science ®Google Scholar
• Janssen JM, Dorlo TPC, Steeghs N, et al. Pharmacokinetic targets for therapeutic drug monitoring of small molecule kinase inhibitors in pediatric oncology. Clin Pharmacol Ther. 2020;108(3):494–505. doi: 10.1002/cpt.1808
   PubMed Web of Science ®Google Scholar
• Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79(3):395–404. doi: 10.1111/bcp.12267
   PubMed Web of Science ®Google Scholar
• Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood. 2012;119(8):1821–1830. doi: 10.1182/blood-2011-10-380774
   PubMed Web of Science ®Google Scholar
• Pena MÁ, Muriel J, Saiz-Rodríguez M, et al. Effect of cytochrome P450 and ABCB1 polymorphisms on imatinib pharmacokinetics after single-dose administration to healthy subjects. Clin Drug Investig. 2020;40(7):617–628. doi: 10.1007/s40261-020-00921-7
   PubMed Web of Science ®Google Scholar
• Nath A, Wang J, Stephanie Huang R. Pharmacogenetics and pharmacogenomics of targeted therapeutics in chronic myeloid leukemia. Mol Diagn Ther. 2017;21(6):621–631. doi: 10.1007/s40291-017-0292-x
   PubMed Web of Science ®Google Scholar
• Eechoute K, Sparreboom A, Burger H, et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res. 2011;17(3):406–415. doi: 10.1158/1078-0432.CCR-10-2250
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M, Scott SA, et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet. 2010;55(11):731–737. doi: 10.1038/jhg.2010.98
   PubMed Web of Science ®Google Scholar
• Dalle Fratte C, Polesel J, Gagno S, et al. Impact of ABCG2 and ABCB1 polymorphisms on imatinib plasmatic exposure: an original work and meta-analysis. Int J Mol Sci. 2023;24(4):3303. doi: 10.3390/ijms24043303
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2(2):117–125. doi: 10.1016/S1535-6108(02)00096-X
   PubMed Web of Science ®Google Scholar
• Bouchet S, Titier K, Moore N, et al. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol. 2013;27(6):690–697. doi: 10.1111/fcp.12007
   PubMed Web of Science ®Google Scholar
• Patel B, Kirkwood AA, Dey A, et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017;31(1):58–64. doi: 10.1038/leu.2016.219
   PubMed Web of Science ®Google Scholar
• Luo X, Li T, Yu Z, et al. The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes. Xenobiotica. 2019;49(7):753–761. doi: 10.1080/00498254.2018.1473662
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer. 2003;89(10):1855–1859. doi: 10.1038/sj.bjc.6601152
   PubMed Web of Science ®Google Scholar
• Diczfalusy U, Nylén H, Elander P, et al. 4β-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol. 2011;71(2):183–189. doi: 10.1111/j.1365-2125.2010.03773.x
   PubMed Web of Science ®Google Scholar
• Haouala A, Widmer N, Duchosal MA, et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):e75–e87. doi: 10.1182/blood-2010-07-294330
   PubMed Web of Science ®Google Scholar
• Thastrup M, Marquart HV, Levinsen M, et al. Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic society of pediatric hematology and oncology study. Leukemia. 2020;34(2):336–346. doi: 10.1038/s41375-019-0570-1
   PubMed Web of Science ®Google Scholar
• Paul S, Short NJ. Central nervous system involvement in adults with acute leukemia: diagnosis, prevention, and management. Curr Oncol Rep. 2022;24(4):427–436. doi: 10.1007/s11912-022-01220-4
   PubMed Web of Science ®Google Scholar
• Thastrup M, Duguid A, Mirian C, et al. Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions. Leukemia. 2022;36(12):2751–2768. doi: 10.1038/s41375-022-01714-x
   PubMed Web of Science ®Google Scholar
• Takayama N, Sato N, O’Brien SG, et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol. 2002;119(1):106–108. doi: 10.1046/j.1365-2141.2002.03881.x
   PubMed Web of Science ®Google Scholar
• Jiang Z-P, Zhao X-L, Takahashi N, et al. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics. 2017;18(1):35–56. doi: 10.2217/pgs-2016-0103
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022–4028. doi: 10.1182/blood-2007-10-116475
   PubMed Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109(8):3496–3499. doi: 10.1182/blood-2006-07-036012
   PubMed Web of Science ®Google Scholar
• Guilhot F, Hughes TP, Cortes J, et al. Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. Haematologica. 2012;97(5):731–738. doi: 10.3324/haematol.2011.045666
   PubMed Web of Science ®Google Scholar
• García-Ferrer M, Wojnicz A, Mejía G, et al. Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis. Clin Ther. 2019;41(12):2558–2570.e7. doi: 10.1016/j.clinthera.2019.10.009
   PubMed Web of Science ®Google Scholar
• DMCG. Kliniske retningslinjer | Kræft: Kronisk myeloid leukæmi, BCR-ABL1-positiv (CML), version 1.0. 2020.
   Google Scholar
• Abdul–Aziz MH, Brady K, Cotta MO, et al. Therapeutic drug monitoring of antibiotics: defining the therapeutic range. Ther Drug Monit. 2022;44(1):19–31. doi: 10.1097/FTD.0000000000000940
   PubMed Web of Science ®Google Scholar
• Hiemke C, Dragicevic A, Gründer G, et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit. 2004;26(2):156–160. doi: 10.1097/00007691-200404000-00012
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526–548. doi: 10.1097/FTD.0000000000000546
   PubMed Web of Science ®Google Scholar
• Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002;24(3):330–350. doi: 10.1016/S0149-2918(02)85038-X
   PubMed Web of Science ®Google Scholar
• Miura M, Takahashi N. Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC–UV or LC–MS/MS methods. Drug Metab Pharmacokinet. 2016;31(1):12–20. doi: 10.1016/j.dmpk.2015.09.002
   PubMed Web of Science ®Google Scholar
• Gotta V, Widmer N, Montemurro M, et al. Therapeutic drug monitoring of imatinib bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012;51(3):187–201. doi: 10.2165/11596990-000000000-00000
   PubMed Web of Science ®Google Scholar
• Erçalışkan A, Seyhan Erdoğan D, Eşkazan AE. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Adv. 2021;5(17):3344–3353. doi: 10.1182/bloodadvances.2021004194
   PubMed Web of Science ®Google Scholar
• Buclin T, Thoma Y, Widmer N, et al. The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib. Front Pharmacol. 2020;11:11. doi: 10.3389/fphar.2020.00177
   PubMed Web of Science ®Google Scholar
• Johnson-Ansah H, Maneglier B, Huguet F, et al. Imatinib optimized therapy improves major molecular response rates in patients with chronic myeloid leukemia. Pharmaceutics. 2022;14(8):14. doi: 10.3390/pharmaceutics14081676
   Web of Science ®Google Scholar
• Cheng F, Zeng F, Li Q, et al. Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia. Cancer. 2022;128(22):3951–3958. doi: 10.1002/cncr.34478
   PubMed Web of Science ®Google Scholar
• Gotta V, Widmer N, Decosterd LA, et al. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chem Pharmacol. 2014;74(6):1307–1319. doi: 10.1007/s00280-014-2599-1
   PubMed Web of Science ®Google Scholar